Amgen Oncology is leading the development of novel therapies that specifically harness the body’s T cells, pioneering the first immuno-oncology program using a BiTE®, or bispecific T cell engager. Explore the world of BiTE® immunotherapy as Amgen scientists Dr. Dirk Nagorsen and Dr. Peter Kufer discuss the current cancer treatment landscape, explain how BiTE® works and offer a preview of how Amgen is bringing this technology into the future of cancer treatment.

This is going to be just the information anybody around the world needs to know.

We need long life expectancy irrespective of what's happening around us.

Good job